[Choose which method for the chemotherapy of epithelial ovarian carcinoma: a meta-analysis].
OBJECTIVE
To evaluate the differences of clinical efficacy between intraperitoneal and intravenous chemotherapy.


METHODS
The literature database was extensively searched to retrieve the randomized controlled trials with a relevance of study goal. The strict inclusion and exclusion criteria were formulated. And the original studies were selected. After a quality evaluation, the data were extracted. The Cochrane collaboration Revman 4.2 version software was used for meta-analysis.


RESULTS
Five clinical studies were included and there were a total of 1 229 eligible patients. Intraperitoneal chemotherapy and intravenous chemotherapy groups were compared: (1) 2 and 3-year progression-free survival (PFS) increased, 2, 3 and 5-year overall survival (OS) increased. The difference was significant enough so that definite conclusions could be drawn; (2) Among the six indicators of unpleasant chemotherapeutic effects (leucopenia, anemia, thrombopenia, GI tract reactions, neurotoxicity and fever), the occurrence of gastrointestinal reaction increased. The difference was significant enough so that definite conclusions could be drawn. And the remaining five indicators had no statistical significance so that definite conclusions could not be drawn.


CONCLUSIONS
For patients with epithelial ovarian cancer (Stages FIGOII-IV) undergoing previously a satisfactory tumor reduction surgery (postoperative residual lesions < 1 to 2 cm), intraperitoneal chemotherapy can improve their 2 and 3-year PFS rates and the 2, 3 and 5-year OS rates; Intraperitoneal chemotherapy has not reduced the side effects. But there is an elevated occurrence of gastrointestinal reactions.
Cui
Ying
Y
Department of Gynecology, the Second Hospital, Jilin University, Changchun 130041, China.
Cui
Man-Hua
MH
Jia
Yan
Y
D002277:Carcinoma / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal / Q000009:adverse effects; D007275:Injections, Intravenous / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome